Pharmaceutical process chemistry for synthesis : Rethinking the routes to scale-up
By: Harrington, Peter J
.
Publisher: New Jercy John Wiley & Sons 2011Description: 369p. | Binding- Hard Bound | 29*22.5 cm.ISBN: 9780470577554.Subject(s): PHARMACEUTICAL CHEMISTRY | Actos® (Pioglitazone Hydrochloride) | Lexapro® (Escitalopram Oxalate) | Efferox XR® (Venlafaxine Hydrochloride) | Seroquel® (Quetiapine Hemifumarate) | Singulair® (Montelukast Sodium) | Prevacid® (Lansoprazole) | Advair Diskus® (Salmeterol Xinafoate) | Lipitor® (Aatorvastatin Calcium)DDC classification: 615.19 Online resources: Explore NDL India For More Resources Summary: There is a need to explain that generic versions of a drug may not be manufactured by the same process as brand-name drugs and that the different processes may have dramatically different environmental impacts. Two global forces are at odds today—the push for "greener" processes and the push for lower drug prices. This book brings this conflict into sharp focus by discussing in detail the published process chemistry for top-selling small molecule drugs.
Providing insights about process route selection, choice of reagents, and reaction conditions, Pharmaceutical Process Chemistry for Synthesis guides process chemists in identifying best processes for manufacturing these blockbuster drugs as they lose patent protection. Further, it highlights the strategies and methodology that might be useful for expediting the process research and development of the blockbusters of the future.
Written from a refreshingly objective perspective, this book is essential for process chemists who need to devise practical syntheses for increasingly complex drugs in a constantly decreasing time frame.
| Item type | Current location | Collection | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|---|
Text Books
|
School of Pharmacy Reference Section | Reference | 615.19 HAR (Browse shelf) | Not For Loan | B3903 |
There is a need to explain that generic versions of a drug may not be manufactured by the same process as brand-name drugs and that the different processes may have dramatically different environmental impacts. Two global forces are at odds today—the push for "greener" processes and the push for lower drug prices. This book brings this conflict into sharp focus by discussing in detail the published process chemistry for top-selling small molecule drugs.
Providing insights about process route selection, choice of reagents, and reaction conditions, Pharmaceutical Process Chemistry for Synthesis guides process chemists in identifying best processes for manufacturing these blockbuster drugs as they lose patent protection. Further, it highlights the strategies and methodology that might be useful for expediting the process research and development of the blockbusters of the future.
Written from a refreshingly objective perspective, this book is essential for process chemists who need to devise practical syntheses for increasingly complex drugs in a constantly decreasing time frame.
There are no comments for this item.